International Journal of Hematology

, Volume 90, Issue 3, pp 303–310 | Cite as

Clinicopathological study on peripheral T-cell non-Hodgkin lymphoma with bone marrow involvement: a retrospective analysis from China

  • Hongyan Tong
  • Yanling Ren
  • Wenbin Qian
  • Feng Xiao
  • Wenyuan Mai
  • Haitao Meng
  • Jie Jin
Original Article


We reviewed 173 patients with an initial diagnosis of peripheral T-cell non-Hodgkin lymphoma (PTCL) and compared the patients with bone marrow involvement (BMI) to those without to have a better understanding of the clinical characteristics, treatments, survival and prognosis of PTCLs with BMI. We found that 40% (70/173) of the patients had BMI, and its frequency was 64% in angioimmunoblastic T-cell lymphoma (TCL), 46% in PTCL unspecified, 29% in anaplastic large T-cell lymphoma, 23% in extranodal NK/T-cell lymphoma and 13% in enteropathy-type TCL. In the BMI group, 36% of patients had lymphoma-associated hemophagocytic syndrome (LAHS), compared with 8% of the patients without BMI (8/103, P < 0.001). The estimated 1-year overall survival (OS) rates of patients with LAHS in the BMI and non-BMI groups were 5 and 49%, respectively. The increased levels of lactate dehydrogenase, fasting triglycerides and β2-microglobulin between the BMI and non-BMI groups were not significantly different, but ferritin increased significantly and liver dysfunction-related diseases were seen more in the BMI group. As much as 51% of patients of the BMI group had anemia, compared with 27% of the patients without BMI (P = 0.001). The estimated 2-year OS rates in the two groups were 10 and 34%. The estimated 2-year OS rate of the 67 patients with BMI, who did not lose to follow-up, was 22%, compared with 38% in the non-BMI group. The median survival times of the 2 groups were 120 and 356 days. The estimated 2-year OS rate of patients treated by CHOP regimen was 9%, compared with 51% of those with intensive chemotherapy, with a significant difference (log rank P = 0.0008). The median survival time of the 14 patients subjected to chemotherapy combined with l-asparaginase was 365 days and that of the 7 patients undergoing hemopoietic stem cell transplantation (HSCT) was 575 days. A total of 3 patients in a critical condition underwent plasmapheresis as initial therapy and achieved stable condition. We conclude that patients with PTCLs with BMI on initial diagnosis usually have hemaphagocytic syndrome and poor prognosis. BMI without lymphadenopathy is a patent clinical feature in most PTCLs. Patients with anemia on initial diagnosis in the BMI group usually have poor prognosis than those without. Intense chemotherapy, addition of l-asparaginase in chemotherapy and HSCT are comparatively efficient treatments of PTCLs. For patients in critical conditions, plasmapheresis before chemotherapy would lower the risk and improve the tolerance to chemotherapy.


T-cell lymphoma Bone marrow involvement Lymphoma-associated hemophagocytic syndrome Overall survival Chemotherapy 



This work was supported by the Medical Science Research Fund of Zhejiang Province (No 2007B079) and also by the help of the Case Management Center of the First Affiliated Hospital of Medical College, Zhejiang University. We thank our interns for collecting and conducting the follow-up.


  1. 1.
    The Non-Hodgkin’s Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin’s lymphoma. Blood. 1997;89:3909–18.Google Scholar
  2. 2.
    Gallamini A, Stelitano C, Calvi R, Bellei M, Mattei D, Vitolo U, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103(7):2474–9. doi: 10.1182/blood-2003-09-3080.CrossRefPubMedGoogle Scholar
  3. 3.
    Yuan XL, Li QC, Zou DH, Zhao YZ, Wang YF, Wang Y, et al. Retrospective analysis of 54 patients with high-risk aggressive T-cell non-Hodgkin lymphomas. Zhonghua Xue Ye Xue Za Zhi. 2007;28(7):454–7.PubMedGoogle Scholar
  4. 4.
    Yamaguchi M, Seto M, Okamoto M, Ichinohasama R, Nakamura N, Yoshino T, et al. De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood. 2002;99(3):815–21. doi: 10.1182/blood.V99.3.815.CrossRefPubMedGoogle Scholar
  5. 5.
    Janka GE, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Br J Haematol. 2004;124(1):4–14. doi: 10.1046/j.1365-2141.2003.04726.x.CrossRefPubMedGoogle Scholar
  6. 6.
    Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol. 2004;127:140–54. doi: 10.1111/j.1365-2141.2004.05144.x.CrossRefPubMedGoogle Scholar
  7. 7.
    López-Guillermo A, Cid J, Salar A, López A, Montalbán C, Castrillo JM, et al. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol. 1998;9(8):849–55. doi: 10.1023/A:1008418727472.CrossRefPubMedGoogle Scholar
  8. 8.
    Fraga M, Brousset P, Schlaifer D, Payen C, Robert A, Rubie H, et al. Bone marrow involvement in anaplastic large cell lymphoma: immunohistochemical detection of minimal disease and its progonostic significance. Am J Clin Pathol. 1995;103(1):82–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Sung CO, Ko YH. Bone marrow is involved in less than 10% of patients with nasal-type NK/T-cell lymphoma at initial diagnosis. J Korean Med Sci. 2004;19(2):229–33.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Siu LL, Chan JK, Kwong YL. Natural killer cell malignancies: clinicopathologic and molecular features. Histol Histopathol. 2002;17(2):539–54.PubMedGoogle Scholar
  11. 11.
    Gaulard P, Kanavaros P, Farcet JP, Rocha FD, Haioun C, Divine M, et al. Bone marrow histologic and immunohistochemical findings in peripheral T-cell lymphoma: a study of 38 cases. Hum Pathol. 1991;22(4):331–8. doi: 10.1016/0046-8177(91)90081-Y.CrossRefPubMedGoogle Scholar
  12. 12.
    Ghani AM, Krause JR. Bone marrow biopsy findings in angioimmunoblastic lymphadenopathy. Br J Haematol. 1985;61(2):203–13. doi: 10.1111/j.1365-2141.1985.tb02819.x.CrossRefPubMedGoogle Scholar
  13. 13.
    Tong H, Ren Y, Liu H, Xiao F, Mai W, Meng H, et al. Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: comparison of T-cell lymphoma with and without hemophagocytic syndrome. Leuk Lymphoma. 2008;49(1):81–7. doi: 10.1080/10428190701713630.CrossRefPubMedGoogle Scholar
  14. 14.
    Hasenclever D, Diehl VA. Prognostic score for advanced Hodgkin’s disease: International Prognostic Factors Project on Advanced Hodgkin’s Disease. N Engl J Med. 1998;339(21):1506–14. doi: 10.1056/NEJM199811193392104.CrossRefPubMedGoogle Scholar
  15. 15.
    Chung R, Lai R, Wei P, Lee J, Hanson J, Belch AR, et al. Concordant but not discordant bone marrow involvement in diffuse large B-cell lymphoma predicts a poor clinical outcome independent of the International Prognostic Index. Blood. 2007;110(4):1278–82. doi: 10.1182/blood-2007-01-070300.CrossRefPubMedGoogle Scholar
  16. 16.
    Peng YL, Huang HQ, Zhou ZM, Lin XB, Pang ZH, Guan ZZ. Clinical outcome of 117 patients with peripheral T-cell lymphomas, unspecified. China Oncol. 2006;16:132–5.Google Scholar
  17. 17.
    Tsimberidou AM, Giles F, Duvic M, Fayad L, Kurzrock R. Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series. Cancer. 2004;100(2):342–9. doi: 10.1002/cncr.11899.CrossRefPubMedGoogle Scholar
  18. 18.
    Morabito F, Gallamini A, Stelitano C, Callea V, Guglielmi C, Neri S, et al. Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi. Cancer. 2004;101(7):1601–8. doi: 10.1002/cncr.20531.CrossRefPubMedGoogle Scholar
  19. 19.
    Kim K, Kim WS, Jung CW, Im YH, Kang WK, Lee MH, et al. Clinical features of peripheral T-cell lymphomas in 78 patients diagnosed according to the REAL classification. Eur J Cancer. 2002;38(1):75–81. doi: 10.1016/S0959-8049(01)00344-6.CrossRefPubMedGoogle Scholar
  20. 20.
    Arrowsmith ER, Macon WR, Kinney MC, Stein RS, Goodman SA, Morgan DS, et al. Peripheral T-cell lymphomas: clinical features and prognostic factors of 92 cases defined by the revised European American Lymphoma Classification. Leuk Lymphoma. 2003;44(2):241–9. doi: 10.1080/1042819021000030054.CrossRefPubMedGoogle Scholar
  21. 21.
    Rüdiger T, Weisenburger DD, Anderson JR, Armitage JO, Diebold J, MacLennan KA, et al. Non-Hodgkin’s Lymphoma Classification Project: peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma) results from the Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 2002;13(1):140–9. doi: 10.1093/annonc/mdf033.CrossRefPubMedGoogle Scholar
  22. 22.
    Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84(5):1361–92.PubMedGoogle Scholar
  23. 23.
    Zaja F, Russo D, Silvestri F, Fanin R, Damiani D, Infanti L, et al. Retrospective analysis of 23 cases with peripheral T-cell lymphomas, unspecified: clinical characteristics and outcome. Haematologica. 1997;82(2):171–7.PubMedGoogle Scholar
  24. 24.
    Rezania D, Cualing HD, Ayala E. The diagnosis, management, and role of hematopoietic stem cell transplantation in aggressive peripheral T-cell neoplasms. Cancer Control. 2007;14(2):151–9. doi: 10.1007/978-1-59745-224-3.CrossRefPubMedGoogle Scholar
  25. 25.
    Yong W, Zhang Y, Zheng W. The efficacy of l-asparaginase in the treatment of refractory midline peripheral T-cell lymphoma. Zhonghua Xue Ye Xue Za Zhi. 2000;21(11):577–9.PubMedGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2009

Authors and Affiliations

  • Hongyan Tong
    • 1
    • 2
  • Yanling Ren
    • 1
    • 2
  • Wenbin Qian
    • 1
    • 2
  • Feng Xiao
    • 1
    • 2
  • Wenyuan Mai
    • 1
    • 2
  • Haitao Meng
    • 1
    • 2
  • Jie Jin
    • 1
    • 2
  1. 1.Department of HematologyThe First Affiliated Hospital, Zhejiang University, College of MedicineHangzhouPeople’s Republic of China
  2. 2.Institute of HematologyZhejiang UniversityHangzhouPeople’s Republic of China

Personalised recommendations